{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:14:50Z","timestamp":1779912890098,"version":"3.53.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"DOI":"10.7759\/cureus.44125","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T21:50:17Z","timestamp":1693000217000},"source":"Crossref","is-referenced-by-count":5,"title":["A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Streptokinase in the Management of Myocardial Infarction in Developing Countries"],"prefix":"10.7759","author":[{"given":"Chioma G","family":"Muoghalu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndianabasi","family":"Ekong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmas C","family":"Ofoegbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danvictor A","family":"Ebirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra T","family":"Alex-Ojei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Cardiovascular diseases. (2021). Accessed. Oct 1, 2022: https:\/\/www.who.int\/news-room\/fact-sheets."},{"key":"ref2","article-title":"Pathophysiology of acute coronary syndromes","author":"Gelfand E V","year":"2009","unstructured":"Gelfand E V, Cannon CP. Pathophysiology of acute coronary syndromes. John Wiley & Sons, Hoboken, New Jersey, U.S.; 2009."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez B","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al.. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018, 39:119-77. 10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.1997.03550230069040","article-title":"Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review","volume":"238","author":"Weaver WD","year":"1997","unstructured":"Weaver WD, Simes RJ, Betriu A, et al.. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997, 238:2093-8. 10.1001\/JAMA.1997.03550230069040","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001038","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Lawton JS","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, et al.. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022, 145:e18-e114. 10.1161\/CIR.0000000000001038","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.07.029","article-title":"Management of acute coronary syndromes in developing countries: acute coronary events-a multinational survey of current management strategies","volume":"162","year":"2011","unstructured":"Management of acute coronary syndromes in developing countries. acute coronary events-a multinational survey of current management strategies. Am Heart J. 2011, 162:852-859.e22. 10.1016\/j.ahj.2011.07.029","journal-title":"Am Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.acmx.2017.10.006","article-title":"Reperfusion of myocardial infarction in India: notions for M\u00e9xico","volume":"88","author":"Araiza-Garaygordobil D","year":"2018","unstructured":"Araiza-Garaygordobil D, Arias-Mendoza A, Mart\u00ednez-S\u00e1nchez C, Mart\u00ednez-R\u00edos MA, Ajit MS. Reperfusion of myocardial infarction in India: notions for M\u00e9xico. Arch Cardiol Mex. 2018, 88:148-52. 10.1016\/j.acmx.2017.10.006","journal-title":"Arch Cardiol Mex"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000107732","article-title":"Kuwait acute coronary syndromes registry: baseline characteristics, management practices and in-hospital outcomes of patients hospitalized with acute coronary syndromes in Kuwait","volume":"16","author":"Zubaid M","year":"2007","unstructured":"Zubaid M, Rashed WA, Saad H, et al.. Kuwait acute coronary syndromes registry: baseline characteristics, management practices and in-hospital outcomes of patients hospitalized with acute coronary syndromes in Kuwait. Med Princ Pract. 2007, 16:407-12. 10.1159\/000107732","journal-title":"Med Princ Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1201\/9781315381770","article-title":"Thrombolytic therapy","author":"Chou EL","year":"2016","unstructured":"Chou EL, Kabutey NK. Thrombolytic therapy. Vascular surgery principles and practice, fourth edition. Wilson SE, Jimenez JC, Veith JF, Naylor AR, Buckels JA (ed): Taylor & Francis Group, Boca Raton; 2016. 123-132. 10.1201\/9781315381770"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.057","article-title":"Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction","volume":"43","author":"Waters RE 2nd","year":"2004","unstructured":"Waters RE 2nd, Singh KP, Roe MT, et al.. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004, 43:2153-9. 10.1016\/j.jacc.2003.12.057","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100503","article-title":"Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand","volume":"26","author":"Trerayapiwat K","year":"2022","unstructured":"Trerayapiwat K, Jinatongthai P, Vathesatogkit P, et al.. Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand. Lancet Reg Health West Pac. 2022, 26:100503. 10.1016\/j.lanwpc.2022.100503","journal-title":"Lancet Reg Health West Pac"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.5.791","article-title":"Safety and efficacy of tenecteplase in acute myocardial infarction","volume":"4","author":"Guerra DR","year":"2003","unstructured":"Guerra DR, Karha J, Gibson CM. Safety and efficacy of tenecteplase in acute myocardial infarction. Expert Opin Pharmacother. 2003, 4:791-8. 10.1517\/14656566.4.5.791","journal-title":"Expert Opin Pharmacother"},{"key":"ref13","article-title":"Comparison of safety and efficacy of streptokinase and tenecteplase in patients of myocardial infarction","volume":"18","author":"Chakka G","year":"2019","unstructured":"Chakka G, Dornadula G, Gundlapalli P, Nuthalapati R, Manupoti Y. Comparison of safety and efficacy of streptokinase and tenecteplase in patients of myocardial infarction.  IOSR J Dent Med Sci. 2019, 18:14-8.","journal-title":"IOSR J Dent Med Sci"},{"key":"ref14","article-title":"Fibrinolytic therapy with streptokinase vs tenecteplase for patients with ST-elevation MI not amenable to primary PCI","volume":"18","author":"Yazdi AH","year":"2017","unstructured":"Yazdi AH, Khalilipur E, Zahedmehr A, et al.. Fibrinolytic therapy with streptokinase vs tenecteplase for patients with ST-elevation MI not amenable to primary PCI. Iran Heart J. 2017, 18:43-9.","journal-title":"Iran Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s3848","article-title":"Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction","volume":"5","author":"Melandri G","year":"2009","unstructured":"Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009, 5:249-56. 10.2147\/vhrm.s3848","journal-title":"Vasc Health Risk Manag"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31441-1","article-title":"Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis","volume":"390","author":"Jinatongthai P","year":"2017","unstructured":"Jinatongthai P, Kongwatcharapong J, Foo CY, et al.. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet. 2017, 390:747-59. 10.1016\/S0140-6736(17)31441-1","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2020.1.45279","article-title":"Using tenecteplase for acute ischemic stroke: what is the hold up?","volume":"21","author":"Zitek T","year":"2020","unstructured":"Zitek T, Ataya R, Brea I. Using tenecteplase for acute ischemic stroke: what is the hold up?. West J Emerg Med. 2020, 21:199-202. 10.5811\/westjem.2020.1.45279","journal-title":"West J Emerg Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00117-0","article-title":"One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction","volume":"146","author":"Sinnaeve P","year":"2003","unstructured":"Sinnaeve P, Alexander J, Belmans A, et al.. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. Am Heart J. 2003, 146:27-32. 10.1016\/S0002-8703(03)00117-0","journal-title":"Am Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.23.2862","article-title":"Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1","volume":"103","author":"Armstrong PW","year":"2001","unstructured":"Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation. 2001, 103:2862-6. 10.1161\/01.cir.103.23.2862","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.040","article-title":"Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events","volume":"108","author":"Awad HH","year":"2011","unstructured":"Awad HH, Zubaid M, Alsheikh-Ali AA, Al Suwaidi J, Anderson FA Jr, Gore JM, Goldberg RJ. Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events. Am J Cardiol. 2011, 108:1252-8. 10.1016\/j.amjcard.2011.06.040","journal-title":"Am J Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.02.071","article-title":"Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry","volume":"51","author":"Chakrabarti A","year":"2008","unstructured":"Chakrabarti A, Krumholz HM, Wang Y, Rumsfeld JS, Nallamothu BK. Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. J Am Coll Cardiol. 2008, 51:2442-3. 10.1016\/j.jacc.2008.02.071","journal-title":"J Am Coll Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/0003319710369794","article-title":"Utilization and determinants of in-hospital cardiac catheterization in patients with acute coronary syndrome from the Middle East","volume":"61","author":"Panduranga P","year":"2010","unstructured":"Panduranga P, Sulaiman K, Al-Zakwani I, et al.. Utilization and determinants of in-hospital cardiac catheterization in patients with acute coronary syndrome from the Middle East. Angiology. 2010, 61:744-50. 10.1177\/0003319710369794","journal-title":"Angiology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg016","article-title":"Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review","volume":"96","author":"Dundar Y","year":"2003","unstructured":"Dundar Y, Hill R, Dickson R, Walley T. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM. 2003, 96:103-13. 10.1093\/qjmed\/hcg016","journal-title":"QJM"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","article-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Cochrane handbook for systematic reviews of interventions. Higgins JPT, Thomas J, Chandler J, et al (ed). John Wiley & Sons, Hoboken, New Jersey, U.S; 2019. 10.1002\/9781119536604"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD201601","article-title":"A revised tool for assessing risk of bias in randomized trials","author":"Higgins JPT","year":"2016","unstructured":"Higgins JPT, Sterne JAC, Savovi\u0107 J, et al.. A revised tool for assessing risk of bias in randomized trials. Cochrane database of systematic reviews. Chandler J, McKenzie J, Boutron I, Welch V (ed): John Wiley & Sons, Hoboken, New Jersey, U.S.; 2016. 10:28-9. 10.1002\/14651858.CD201601"},{"key":"ref27","unstructured":"Critical appraisal checklists. (2018). Accessed. Dec 20, 2022:  https:\/\/casp-uk.net\/casp-tools-checklists."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01383-x","article-title":"The outcomes of reperfusion therapy with streptokinase versus tenecteplase in ST-elevation myocardial infarction (STEMI): a propensity-matched retrospective analysis in an Asian population","volume":"44","author":"Koh HP","year":"2022","unstructured":"Koh HP, Md Redzuan A, Mohd Saffian S, Nagarajah JR, Ross NT, Hassan H. The outcomes of reperfusion therapy with streptokinase versus tenecteplase in ST-elevation myocardial infarction (STEMI): a propensity-matched retrospective analysis in an Asian population. Int J Clin Pharm. 2022, 44:641-50. 10.1007\/s11096-022-01383-x","journal-title":"Int J Clin Pharm"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.36106\/ijsr\/2601395","article-title":"Clinical evaluation of reperfusion in ST-elevation myocardial infarction with non- invasive markers following thrombolysis with streptokinase versus tenecteplase","volume":"10","author":"Shah S","year":"2021","unstructured":"Shah S, Sukhwani K, Prajapati V, KV S. Clinical evaluation of reperfusion in ST-elevation myocardial infarction with non- invasive markers following thrombolysis with streptokinase versus tenecteplase. Int J Sci Res. 2021, 10:35-8. 10.36106\/ijsr\/2601395","journal-title":"Int J Sci Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4103\/JICC.JICC_62_20","article-title":"Safety and efficacy of streptokinase, tenecteplase, and reteplase in patients diagnosed with st-elevation myocardial infarction: a comparative study","volume":"17","author":"Neela B","year":"2020","unstructured":"Neela B, Gunreddy VR, Chandupatla MR, Eggadi V, Bhava Bandaru SS. Safety and efficacy of streptokinase, tenecteplase, and reteplase in patients diagnosed with st-elevation myocardial infarction: a comparative study. J Indian Coll Cardiol. 2020, 17:134-8. 10.4103\/JICC.JICC_62_20","journal-title":"J Indian Coll Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360X.2020.00032.3","article-title":"Comparative study on streptokinase, reteplase and tenecteplase in the management of ST-elevated myocardial infarction","volume":"13","author":"Nikitha G","year":"2020","unstructured":"Nikitha G, Chowdary KSM, Vani KN, et al.. Comparative study on streptokinase, reteplase and tenecteplase in the management of ST-elevated myocardial infarction. Res J Pharm Technol. 2020, 13:160. 10.5958\/0974-360X.2020.00032.3","journal-title":"Res J Pharm Technol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_297_18","article-title":"Preintensive care: thrombolytic (streptokinase or tenecteplase) in ST elevated acute myocardial infarction at peripheral hospital","volume":"8","author":"Bawaskar HS","year":"2019","unstructured":"Bawaskar HS, Bawaskar PH, Bawaskar PH. Preintensive care: thrombolytic (streptokinase or tenecteplase) in ST elevated acute myocardial infarction at peripheral hospital. J Family Med Prim Care. 2019, 8:62-71. 10.4103\/jfmpc.jfmpc_297_18","journal-title":"J Family Med Prim Care"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7897\/2230-8407.100395","article-title":"Impact of streptokinase and tenecteplase on electrocardiogram (ST-segment) and two dimensional echocardiography (regional wall motion abnormalities) in ST-elevated myocardial infarction","volume":"10","author":"Naini P","year":"2019","unstructured":"Naini P, Punzuri R, Reddy MC, Adla N. Impact of streptokinase and tenecteplase on electrocardiogram (ST-segment) and two dimensional echocardiography (regional wall motion abnormalities) in ST-elevated myocardial infarction. Int Res J Pharm. 2019, 10:154-7. 10.7897\/2230-8407.100395","journal-title":"Int Res J Pharm"},{"key":"ref34","article-title":"A comparative analysis of efficacy of thrombolytics in acute st elevation mi and its variation with circadian rhythm","volume":"8","author":"Singh AK","year":"2019","unstructured":"Singh AK. A comparative analysis of efficacy of thrombolytics in acute st elevation mi and its variation with circadian rhythm. Cardiology . 2019, 8:","journal-title":"Cardiology"},{"key":"ref35","article-title":"A randomized, parallel study to compare efficacy & safety of streptokinase vs tenecteplase when given in correct timelines in patients of st-elevation myocardial infarction (STEMI)","volume":"3","author":"Aherrao N","year":"2018","unstructured":"Aherrao N, Chopda M, Gulecha V, Gulecha V, Upasani C. A randomized, parallel study to compare efficacy & safety of streptokinase vs tenecteplase when given in correct timelines in patients of st-elevation myocardial infarction (STEMI). Ann Pharmacol Pharm. 2018, 3:1159.","journal-title":"Ann Pharmacol Pharm"},{"key":"ref36","article-title":"A comparative study of streptokinase v\/s tenecteplase in hyper acute stage of myocardial infarction","volume":"5","author":"Deshani VR","year":"2016","unstructured":"Deshani VR, Mehta MN, Rathod NR. A comparative study of streptokinase v\/s tenecteplase in hyper acute stage of myocardial infarction. Int J Sci Res. 2016, 5:63-5.","journal-title":"Int J Sci Res"},{"key":"ref37","article-title":"A comparative study of thrombolytics used for the treatment of STEMI in a south Indian tertiary care hospital","volume":"2","author":"Xavier AA","year":"2016","unstructured":"Xavier AA, Chandana R, Sarwar A, Dhanapal CK. A comparative study of thrombolytics used for the treatment of STEMI in a south Indian tertiary care hospital. Res Pharm Heal Sci. 2016, 2:160-2.","journal-title":"Res Pharm Heal Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4103\/1995-705X.99224","article-title":"Clinical profile and mortality of ST-segment elevation myocardial infarction patients receiving thrombolytic therapy in the Middle East","volume":"13","author":"Panduranga P","year":"2012","unstructured":"Panduranga P, Al-Zakwani I, Sulaiman K, et al.. Clinical profile and mortality of ST-segment elevation myocardial infarction patients receiving thrombolytic therapy in the Middle East. Heart Views. 2012, 13:35-41. 10.4103\/1995-705X.99224","journal-title":"Heart Views"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-012-0698-6","article-title":"Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East","volume":"33","author":"Al-Zakwani I","year":"2012","unstructured":"Al-Zakwani I, Ali A, Zubaid M, et al.. Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East. J Thromb Thrombolysis. 2012, 33:280-6. 10.1007\/s11239-012-0698-6","journal-title":"J Thromb Thrombolysis"},{"key":"ref40","article-title":"Safety and efficacy of streptokinase, reteplase and tenecteplase in patients with acute stelevatedmyocardial infarction in an intensive cardiac care unit of a tertiary care teaching hospital","volume":"5","author":"Pelluri R","year":"2014","unstructured":"Pelluri R, Rani NV, Ramesh M, Kannan G. Safety and efficacy of streptokinase, reteplase and tenecteplase in patients with acute stelevatedmyocardial infarction in an intensive cardiac care unit of a tertiary care teaching hospital. Int J Pharma Bio Sci. 2014, 5:29-38.","journal-title":"Int J Pharma Bio Sci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969110-00003","article-title":"Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis","volume":"69","author":"Giraldez RR","year":"2009","unstructured":"Giraldez RR, Wiviott SD, Nicolau JC, Mohanavelu S, Morrow DA, Antman EM, Giugliano RP. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. Drugs. 2009, 69:1433-43. 10.2165\/00003495-200969110-00003","journal-title":"Drugs"},{"key":"ref42","article-title":"The effect direction plot revisited: application of the 2019 Cochrane Handbook guidance on alternative synthesis methods","volume":"12","author":"Boon MH","year":"2021","unstructured":"Boon MH, Thomson H. The effect direction plot revisited: application of the 2019 Cochrane Handbook guidance on alternative synthesis methods. Res Synth Methods. 2021, 12:29-33.","journal-title":"Res Synth Methods"},{"key":"ref43","article-title":"A history of streptokinase use in acute myocardial infarction","volume":"34","author":"Sikri N","year":"2007","unstructured":"Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J. 2007, 34:318-27.","journal-title":"Tex Heart Inst J"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(81)90643-8","article-title":"Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis","volume":"102","author":"Sherry S","year":"1981","unstructured":"Sherry S. Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J. 1981, 102:1134-8. 10.1016\/0002-8703(81)90643-8","journal-title":"Am Heart J"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(60)90348-9","article-title":"Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction","volume":"6","author":"Boucek RJ","year":"1960","unstructured":"Boucek RJ, Murphy WP. Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Am J Cardiol. 1960, 6:525-33. 10.1016\/0002-9149(60)90348-9","journal-title":"Am J Cardiol"},{"key":"ref46","article-title":"Intracoronary administration of fibrinolysin in acute myocardial infarct [Article in Russian]","volume":"48","author":"Chazov EI","year":"1976","unstructured":"Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI. Intracoronary administration of fibrinolysin in acute myocardial infarct [Article in Russian]. Ter Arkh. 1976, 48:8-19.","journal-title":"Ter Arkh"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(84)90297-2","article-title":"Randomized comparison of intravenous versus intracoronary streptokinase for myocardial infarction","volume":"54","author":"Alderman EL","year":"1984","unstructured":"Alderman EL, Jutzy KR, Berte LE, Miller RG, Friedman JP, Creger WP, Eliastam M. Randomized comparison of intravenous versus intracoronary streptokinase for myocardial infarction. Am J Cardiol. 1984, 54:14-9. 10.1016\/0002-9149(84)90297-2","journal-title":"Am J Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197910113011501","article-title":"Streptokinase in acute myocardial infarction","volume":"301","year":"1979","unstructured":"Streptokinase in acute myocardial infarction. N Engl J Med. 1979, 301.797-802. 10.1056\/NEJM197910113011501","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(87)80426-6","article-title":"GISSI trial: early results and late follow-up","volume":"10","author":"Rovelli F","year":"1987","unstructured":"Rovelli F, De Vita C, Feruglio GA, Lotto A, Selvini A, Tognomi G. GISSI trial: early results and late follow-up. J Am Coll Cardiol. 1987, 10:33B-9B. 10.1016\/S0735-1097(87)80426-6","journal-title":"J Am Coll Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(99)00166-7","article-title":"Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks","volume":"34","author":"French JK","year":"1999","unstructured":"French JK, Hyde TA, Patel H, Amos DJ, McLaughlin SC, Webber BJ, White HD. Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. J Am Coll Cardiol. 1999, 34:62-9. 10.1016\/s0735-1097(99)00166-7","journal-title":"J Am Coll Cardiol"},{"key":"ref51","article-title":"Megadose heparin and streptokinase produce similar TIMI 3 flow at discharge in patients of acute myocardial infarction presenting between 7-12 hours","volume":"52","author":"Dwivedi SK","year":"2000","unstructured":"Dwivedi SK, Pramod K, Gupta R, Saran RK, Narain VS, Puri VK. Megadose heparin and streptokinase produce similar TIMI 3 flow at discharge in patients of acute myocardial infarction presenting between 7-12 hours. Indian Heart J. 2000, 52:183-6.","journal-title":"Indian Heart J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(88)92635-6","article-title":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"12","year":"1988","unstructured":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2. J Am Coll Cardiol. 1988, 12:3A-13A. 10.1016\/0735-1097(88)92635-6","journal-title":"J Am Coll Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.92.10.2811","article-title":"Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries","volume":"92","author":"Gore JM","year":"1995","unstructured":"Gore JM, Granger CB, Simoons ML, et al.. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation. 1995, 92:2811-8. 10.1161\/01.cir.92.10.2811","journal-title":"Circulation"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00087-8","article-title":"Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial","volume":"79","author":"Tsang TS","year":"1997","unstructured":"Tsang TS, Califf RM, Stebbins AL, Lee KL, Cho S, Ross AM, Armstrong PW. Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Am J Cardiol. 1997, 79:1232-5. 10.1016\/s0002-9149(97)00087-8","journal-title":"Am J Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1528","article-title":"Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction","volume":"20","author":"Squire IB","year":"1999","unstructured":"Squire IB, Lawley W, Fletcher S, Holme E, Hillis WS, Hewitt C, Woods KL. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J. 1999, 20:1245-52. 10.1053\/euhj.1999.1528","journal-title":"Eur Heart J"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","unstructured":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993, 329.673-82. 10.1056\/NEJM199309023291001","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00188-a","article-title":"Lessons we have learned from the GUSTO trial","volume":"25","author":"Holmes DR Jr","year":"1995","unstructured":"Holmes DR Jr, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. J Am Coll Cardiol. 1995, 25:10S-17S. 10.1016\/0735-1097(95)00188-a","journal-title":"J Am Coll Cardiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311253292204","article-title":"The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction","volume":"329","year":"1993","unstructured":"The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993, 329.1615-22. 10.1056\/NEJM199311253292204","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3670","article-title":"A faster-acting and more potent form of tissue plasminogen activator","volume":"91","author":"Keyt BA","year":"1994","unstructured":"Keyt BA, Paoni NF, Refino CJ, et al.. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994, 91:3670-4. 10.1073\/pnas.91.9.3670","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241150-00001","article-title":"Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction","volume":"41","author":"Tanswell P","year":"2002","unstructured":"Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002, 41:1229-45. 10.2165\/00003088-200241150-00001","journal-title":"Clin Pharmacokinet"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.98.25.2805","article-title":"TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators","volume":"98","author":"Cannon CP","year":"1998","unstructured":"Cannon CP, Gibson CM, McCabe CH, et al.. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998, 98:2805-14. 10.1161\/01.cir.98.25.2805","journal-title":"Circulation"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)07403-6","article-title":"Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial","volume":"354","author":"Van de Werf F","year":"1999","unstructured":"Van de Werf F. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999, 354:716-22. 10.1016\/s0140-6736(99)07403-6","journal-title":"Lancet"},{"key":"ref63","article-title":"European Society of Cardiology 2000. Amsterdam, The Netherlands, 26-30 August, 2000","volume":"1","author":"Davies C","year":"2001","unstructured":"Davies C. European Society of Cardiology 2000. Amsterdam, The Netherlands, 26-30 August, 2000. Heart Fail Monit. 2001, 1:107-9.","journal-title":"Heart Fail Monit"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.4.442","article-title":"Bolus fibrinolytic therapy in acute myocardial infarction","volume":"286","author":"Llevadot J","year":"2001","unstructured":"Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA. 2001, 286:442-9. 10.1001\/jama.286.4.442","journal-title":"JAMA"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(96)00739-4","article-title":"Clinical trials in thrombolytic therapy: what do they tell us? Inject 6-month outcomes data","volume":"78","author":"Wilcox RG","year":"1996","unstructured":"Wilcox RG. Clinical trials in thrombolytic therapy: what do they tell us? Inject 6-month outcomes data. Am J Cardiol. 1996, 78:20-3. 10.1016\/s0002-9149(96)00739-4","journal-title":"Am J Cardiol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.5200\/sm-hs.2012.107","article-title":"Treatment of acute stemi with thrombolysis: tenecteplase vs. streptokinase","volume":"5","author":"\u0160erpytis P","year":"2012","unstructured":"\u0160erpytis P, Bilkis V, Kakliorius R, et al.. Treatment of acute stemi with thrombolysis: tenecteplase vs. streptokinase. Sveik Moksl. 2012, 5:110-3. 10.5200\/sm-hs.2012.107","journal-title":"Sveik Moksl"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2013.08.009","article-title":"The report on the Indian coronary intervention data for the year 2011--National Interventional Council","volume":"65","author":"Ramakrishnan S","year":"2013","unstructured":"Ramakrishnan S, Mishra S, Chakraborty R, Chandra KS, Mardikar HM. The report on the Indian coronary intervention data for the year 2011--National Interventional Council. Indian Heart J. 2013, 65:518-21. 10.1016\/j.ihj.2013.08.009","journal-title":"Indian Heart J"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.07.039","article-title":"Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality","volume":"245","author":"Rossell\u00f3 X","year":"2017","unstructured":"Rossell\u00f3 X, Huo Y, Pocock S, et al.. Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. Int J Cardiol. 2017, 245:27-34. 10.1016\/j.ijcard.2017.07.039","journal-title":"Int J Cardiol"},{"key":"ref69","article-title":"Thai Registry in Acute Coronary Syndrome (TRACS)--an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year","volume":"95","author":"Srimahachota S","year":"2012","unstructured":"Srimahachota S, Boonyaratavej S, Kanjanavanit R, et al.. Thai Registry in Acute Coronary Syndrome (TRACS)--an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year. J Med Assoc Thai. 2012, 95:508-18.","journal-title":"J Med Assoc Thai"},{"key":"ref70","unstructured":"Thai acute coronary syndromes guidelines 2020. Bangkok: the heart association of Thailand under the royal patronage of H.M. the king. (2020). Accessed: Dec 20, 2022:  http:\/\/www.thaiheart.org\/Thai-ACS-Guidelines-2020."},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara PT","year":"2013","unstructured":"O'Gara PT, Kushner FG, Ascheim DD, et al.. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013, 127:529-55. 10.1161\/CIR.0b013e3182742c84","journal-title":"Circulation"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2090","article-title":"Real-world comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants vs. Warfarin in a developing country","volume":"109","author":"Mitsuntisuk P","year":"2021","unstructured":"Mitsuntisuk P, Nathisuwan S, Junpanichjaroen A, et al.. Real-world comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants vs. Warfarin in a developing country. Clin Pharmacol Ther. 2021, 109:1282-92. 10.1002\/cpt.2090","journal-title":"Clin Pharmacol Ther"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111634","article-title":"Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"27","author":"Noviyani R","year":"2022","unstructured":"Noviyani R, Youngkong S, Nathisuwan S, et al.. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med. 2022, 27:215-23. 10.1136\/bmjebm-2020-111634","journal-title":"BMJ Evid Based Med"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(12)60462-8","article-title":"A 10-year review of thrombolytic therapy in patients with ST-segment elevation myocardial infarction in a university hospital in Hong Kong – intracranial bleeding and other outcomes","volume":"59","author":"Lam S","year":"2012","unstructured":"Lam S, Lee SW, Chan K. A 10-year review of thrombolytic therapy in patients with ST-segment elevation myocardial infarction in a university hospital in Hong Kong – intracranial bleeding and other outcomes. J Am Coll Cardiol. 2012, 59:E461. 10.1016\/S0735-1097(12)60462-8","journal-title":"J Am Coll Cardiol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1177\/102490791302000605","article-title":"Efficacy and safety of tenectaplase versus streptokinase in treating sT-elevation myocardial infarction patients in Hong Kong: a four-year retrospective review in Queen Elizabeth Hospital","volume":"20","author":"Chau HW","year":"2013","unstructured":"Chau HW, Choi KK. Efficacy and safety of tenectaplase versus streptokinase in treating sT-elevation myocardial infarction patients in Hong Kong: a four-year retrospective review in Queen Elizabeth Hospital. Hong Kong J Emerg Med. 2013, 20:359-63. 10.1177\/102490791302000605","journal-title":"Hong Kong J Emerg Med"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.1691","article-title":"Effectiveness and safety of thrombolytic agents streptokinase, alteplase and tenecteplase in the treatment of acute myocardial infarction","volume":"19","author":"Ascef BO","year":"2016","unstructured":"Ascef BO, Izidoro JB, Almeida AM, Bahia Neto AF, Guerra J\u00fanior AA, Acurcio FA. Effectiveness and safety of thrombolytic agents streptokinase, alteplase and tenecteplase in the treatment of acute myocardial infarction. Value Heal. 2016, 19:640. 10.1016\/j.jval.2016.09.1691","journal-title":"Value Heal"},{"key":"ref77","article-title":"Effectiveness of tenecteplase versus streptokinase in treatment of acute myocardial infarction: a meta-analysis","volume":"76","author":"Tourani S","year":"2018","unstructured":"Tourani S, Bashzar S, Nikfar S, Ravaghi H, Sadeghi M. Effectiveness of tenecteplase versus streptokinase in treatment of acute myocardial infarction: a meta-analysis. Tehran Univ Med J. 2018, 76:380-7.","journal-title":"Tehran Univ Med J"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.303","article-title":"Budget impact analysis of the use of tenecteplase in the treatment of acute myocardial infarction in Mexico","volume":"18","author":"Huicochea-Bartelt J","year":"2015","unstructured":"Huicochea-Bartelt J, Palacios E, Zapata L, Herran S. Budget impact analysis of the use of tenecteplase in the treatment of acute myocardial infarction in Mexico. Value Heal. 2015,  18:A828. 10.1016\/j.jval.2015.09.303","journal-title":"Value Heal"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.03.1499","article-title":"Cost-effectiveness of thrombolysis for myocardial infarction with supra st in Colombia","volume":"16","author":"Rosselli D","year":"2013","unstructured":"Rosselli D, Rueda JD, Moreno A, Herran S. Cost-effectiveness of thrombolysis for myocardial infarction with supra st in Colombia. Value Heal. 2013, 16:PA289. 10.1016\/j.jval.2013.03.1499","journal-title":"Value Heal"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/BF02599951","article-title":"A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction","volume":"10","author":"Kalish SC","year":"1995","unstructured":"Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995, 10:321-30. 10.1007\/BF02599951","journal-title":"J Gen Intern Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505253322106","article-title":"Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction","volume":"332","author":"Mark DB","year":"1995","unstructured":"Mark DB, Hlatky MA, Califf RM, et al.. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995, 332:1418-24. 10.1056\/NEJM199505253322106","journal-title":"N Engl J Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91893-D","article-title":"ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction","volume":"339","year":"1992","unstructured":"ISIS-3. a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992, 339:753-70. 10.1016\/0140-6736(92)91893-D","journal-title":"Lancet"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91589-3","article-title":"GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction","volume":"336","year":"1990","unstructured":"GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet. 1990, 336:65-71. 10.1016\/0140-6736(90)91589-3","journal-title":"Lancet"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710163371603","article-title":"A comparison of reteplase with alteplase for acute myocardial infarction","volume":"337","year":"1997","unstructured":"A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997, 337.1118-23. 10.1056\/NEJM199710163371603","journal-title":"N Engl J Med"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92224-5","article-title":"Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence","volume":"346","author":"Wilcox RG","year":"1995","unstructured":"Wilcox RG. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995, 346:329-36. 10.1016\/S0140-6736(95)92224-5","journal-title":"Lancet"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"Van de Werf F","year":"2008","unstructured":"Van de Werf F, Bax J, Betriu A, et al.. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008, 29:2909-45. 10.1093\/eurheartj\/ehn416","journal-title":"Eur Heart J"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99124-5_31","article-title":"Observational studies: uses and limitations","author":"Hess AS","year":"2019","unstructured":"Hess AS, Abd-Elsayed A. Observational studies: uses and limitations. Pain. Abd-Elsayed A (ed): Springer, Cham, Switzerland; 2019. 123-5. 10.1007\/978-3-319-99124-5_31"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.10.015","article-title":"Relation between thrombolysis in myocardial infarction risk score and one-year outcomes for patients presenting at the emergency department with potential acute coronary syndrome","volume":"105","author":"Weisenthal BM","year":"2010","unstructured":"Weisenthal BM, Chang AM, Walsh KM, Collin MJ, Shofer FS, Hollander JE. Relation between thrombolysis in myocardial infarction risk score and one-year outcomes for patients presenting at the emergency department with potential acute coronary syndrome. Am J Cardiol. 2010, 105:441-4. 10.1016\/j.amjcard.2009.10.015","journal-title":"Am J Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/137856-a-systematic-review-of-the-efficacy-and-safety-of-tenecteplase-versus-streptokinase-in-the-management-of-myocardial-infarction-in-developing-countries","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:15Z","timestamp":1707508575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/137856-a-systematic-review-of-the-efficacy-and-safety-of-tenecteplase-versus-streptokinase-in-the-management-of-myocardial-infarction-in-developing-countries"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":88,"URL":"https:\/\/doi.org\/10.7759\/cureus.44125","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}